NIH R44 funding opportunities: Small Business Innovation Research (SBIR) Phase II
4 NIH notices for R44 (Small Business Innovation Research (SBIR) Phase II) are open and 3 forecast. Full research and development of an SBIR project after...
- Open notices4
- Forecast3
- Projects funded under them11,079
Open NIH R44 notices
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Open - Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
Open - Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
Open - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
Open
Forecast R44 notices
- Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
Forecast - NIEHS Worker Training Program’s SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
Forecast - Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
Forecast
Institutes that fund R44 projects under these notices
| Institute or center | Projects |
|---|---|
| National Cancer Institute (NCI) | 1,570 |
| National Heart Lung and Blood Institute (NHLBI) | 1,244 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1,042 |
| National Institute of General Medical Sciences (NIGMS) | 981 |
| National Institute on Aging (NIA) | 911 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 786 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 745 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 489 |
| National Institute on Drug Abuse (NIDA) | 472 |
| National Institute of Mental Health (NIMH) | 438 |
Closed R44 notices
- RFA-DA-25-048: Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
- PAR-23-311: NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
- RFA-MD-24-006: Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)
- PAR-24-131: Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed)
- PAR-24-132: Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required)
- PAR-24-221: NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)
- PAR-24-222: NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)
- RFA-HL-26-014: NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
- RFA-HL-26-015: NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
- PAS-22-196: Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
- PAR-23-032: Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
- PA-24-247: PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- PA-24-248: PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
- PA-24-246: PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
- PA-24-245: PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- RFA-NS-23-006: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
- PAR-23-213: Interactive Digital Media (IDM) Biomedical Science Resources for Pre-College Students and Teachers (SBIR) (R43/R44 Clinical Trial Not Allowed)
- PAR-24-158: Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed)
- PA-23-189: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
- RFA-DA-26-018: Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional)
- RFA-DA-23-021: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
- PA-25-212: Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)
- PAR-21-225: Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed)
- RFA-DA-25-050: Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)
- PAR-24-263: SBIR Solutions to Enable Population Genomic Screening (R43/R44 Clinical Trial Optional)
- PA-21-345: Administrative Supplements to Promote Diversity in Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed)
- RFA-CA-24-022: SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
- RFA-ES-24-003: SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
- RFA-DA-25-054: Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)
- PA-21-268: Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- PAR-24-106: Solutions to Enable Regional Genomic Medicine eConsult Services (R43/R44 Clinical Trial Optional)
- RFA-AA-24-001: High-Throughput Screening (HTS) Platform for Discovery of Medications to Treat Alcohol Use Disorder (R43/R44 Clinical Trials Not Allowed)
- PAR-21-114: NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)
- PAR-21-265: NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)
- PA-23-231: PHS 2023-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
- PA-23-230: PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- PA-23-232: PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- RFA-DA-25-052: Tools for decentralized clinical trials for substance use disorder (R43/R44 Clinical Trials Optional)
- RFA-HL-23-008: NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
- RFA-HL-23-009: NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
- PAR-22-073: Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)
- PAR-21-297: Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R43/R44 Clinical Trial Not Allowed)
- PAR-21-266: NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
- RFA-DA-24-018: Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional)
- RFA-AG-24-042: NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional)
- RFA-MD-23-003: Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)
- RFA-CA-23-034: SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
- RFA-ES-23-005: SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
- RFA-ES-23-008: Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed)
- PAR-21-247: Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial not allowed)
- PA-22-177: PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
- PA-22-178: PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- PA-22-176: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- RFA-AG-23-029: NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional)
- RFA-HG-21-008: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44)
- RFA-DA-23-017: Therapeutic Development of Psychoplastogenic Compounds for Substance Use Disorders (R43/R44 - Clinical Trials Not Allowed)
- RFA-DA-23-018: Enabling SUD Digital Therapeutics Research to Improve Payor Adoption (R44- Clinical Trial Only)
- RFA-DA-23-020: Novel Drug (DDT) and Medical Device Development Tools (MDDT) to Help Expedite Creation and Regulatory Approvals of New Therapies for Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
- RFA-DE-23-008: Data-Driven Tools to Accelerate the Clinical Translation of Novel Dental, Oral, and Craniofacial Biomaterials (Fast-Track - R44 - Clinical Trial Not Allowed)
- RFA-ES-22-006: New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)
- RFA-DK-21-011: Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)
- RFA-DK-21-012: Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)
- RFA-DK-21-021: Support for Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)
- RFA-ES-22-004: SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
- RFA-CA-22-025: SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
- PA-21-259: PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- PA-21-262: PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- PA-21-261: PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
- PA-21-260: PHS 2021-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
- RFA-MD-22-004: Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)
- RFA-DA-22-023: Advancing Validated Drug Targets for Substance Use Disorders (R43/R44 - Clinical Trial Not Allowed)
- RFA-ES-21-008: Innovative Approaches for Improving Environmental Health Literacy (R43/R44 Clinical Trial Not Allowed)
- RFA-AG-22-007: NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional)
- RFA-DA-22-001: Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (R43/R44 Clinical Trial Optional)
- RFA-DA-22-019: Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R43/R44 - Clinical Trial Not Allowed)
- RFA-CA-21-036: SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
- RFA-ES-21-005: SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
- RFA-HD-22-010: Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional)
- RFA-MD-21-006: Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)
Questions people ask
What is an NIH R44?
R44 is NIH's activity code for the Small Business Innovation Research (SBIR) Phase II. Full research and development of an SBIR project after Phase I (or both phases at once, called Fast Track). Each notice sets its own budget limit, project length and due dates.
How many NIH R44 funding opportunities are open?
4 notices are open on Grants.gov, and 3 more are forecast, as of the latest data.